NL300041I2 - Versterkingsmiddel voor het antineoplastisch effect en antineoplastisch middel. - Google Patents

Versterkingsmiddel voor het antineoplastisch effect en antineoplastisch middel.

Info

Publication number
NL300041I2
NL300041I2 NL300041C NL300041C NL300041I2 NL 300041 I2 NL300041 I2 NL 300041I2 NL 300041 C NL300041 C NL 300041C NL 300041 C NL300041 C NL 300041C NL 300041 I2 NL300041 I2 NL 300041I2
Authority
NL
Netherlands
Prior art keywords
antineoplastic
effect
potentiating
agent
antineoplastic effect
Prior art date
Application number
NL300041C
Other languages
English (en)
Other versions
NL300041I1 (nl
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17034249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300041(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of NL300041I1 publication Critical patent/NL300041I1/nl
Publication of NL300041I2 publication Critical patent/NL300041I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compounds Of Unknown Constitution (AREA)
NL300041C 1990-09-07 2001-03-21 Versterkingsmiddel voor het antineoplastisch effect en antineoplastisch middel. NL300041I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23871990 1990-09-07
PCT/JP1991/001187 WO1992004028A1 (fr) 1990-09-07 1991-09-05 Potentialisateur d'effets antineoplasique et agent antineoplasique

Publications (2)

Publication Number Publication Date
NL300041I1 NL300041I1 (nl) 2001-06-01
NL300041I2 true NL300041I2 (nl) 2002-02-01

Family

ID=17034249

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300041C NL300041I2 (nl) 1990-09-07 2001-03-21 Versterkingsmiddel voor het antineoplastisch effect en antineoplastisch middel.

Country Status (14)

Country Link
EP (1) EP0500953B1 (nl)
JP (1) JP2557303B2 (nl)
KR (1) KR0146952B1 (nl)
AT (1) ATE141506T1 (nl)
AU (1) AU644684B2 (nl)
CA (1) CA2071819A1 (nl)
DE (2) DE69121551T2 (nl)
DK (1) DK0500953T3 (nl)
ES (1) ES2091941T3 (nl)
GR (1) GR3021003T3 (nl)
HU (1) HU211739A9 (nl)
LU (1) LU90791I2 (nl)
NL (1) NL300041I2 (nl)
WO (1) WO1992004028A1 (nl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05310573A (ja) * 1992-05-01 1993-11-22 Dotsuto:Kk リウマチ治療薬
US5643191A (en) * 1995-01-26 1997-07-01 Sorin Biomedical Inc. Cardioplegia delivery system and method for converting from warm cardioplegia to cold cardioplegia
US5702358A (en) * 1995-02-23 1997-12-30 Sorin Biomedical Inc. Cardioplegia delivery apparatus and method of use
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US6538001B1 (en) * 1998-10-12 2003-03-25 Nikolai Borisovich Leonidov Crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl) uracil and complex compounds based thereon, producing antineoplastic effect
NZ542150A (en) 2003-03-14 2009-09-25 Taiho Pharmaceutical Co Ltd Antitumor effect potentiator and antitumor agent
TWI468188B (zh) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
WO2009139085A1 (ja) 2008-05-12 2009-11-19 静岡県 抗腫瘍剤、キット及び癌治療方法
KR102258514B1 (ko) * 2019-09-23 2021-05-31 연세대학교 산학협력단 신규한 다층형 좌약 제제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5953885B2 (ja) * 1978-02-10 1984-12-27 大鵬薬品工業株式会社 抗腫瘍剤組成物
GB2016921B (en) * 1978-03-27 1982-08-18 Taiho Pharmaceutical Co Ltd Anti cancer compositions containing uracil derivatives
JPS5780319A (en) * 1980-11-06 1982-05-19 Taiho Yakuhin Kogyo Kk Anti-tumor agent having reduced toxicity
JPS5838210A (ja) * 1981-08-31 1983-03-05 Taiho Yakuhin Kogyo Kk 直腸投与用製剤

Also Published As

Publication number Publication date
JP2557303B2 (ja) 1996-11-27
DE10299023I1 (de) 2003-06-05
KR0146952B1 (ko) 1998-08-17
ES2091941T3 (es) 1996-11-16
HU211739A9 (en) 1995-12-28
GR3021003T3 (en) 1996-12-31
DE10299023I2 (de) 2010-05-06
WO1992004028A1 (fr) 1992-03-19
LU90791I2 (fr) 2001-10-08
DE69121551T2 (de) 1997-01-02
AU644684B2 (en) 1993-12-16
KR927002224A (ko) 1992-09-03
ATE141506T1 (de) 1996-09-15
DE69121551D1 (de) 1996-09-26
EP0500953B1 (en) 1996-08-21
EP0500953A1 (en) 1992-09-02
CA2071819A1 (en) 1992-03-08
AU8447991A (en) 1992-03-30
EP0500953A4 (en) 1993-04-21
DK0500953T3 (da) 1997-01-06
NL300041I1 (nl) 2001-06-01

Similar Documents

Publication Publication Date Title
ATE136542T1 (de) Pyrimidine und deren pharmazeutisch brauchbare salze und deren verwendung als arzneimittel
NL970006I2 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
DE69318031D1 (de) Ematiomerenreine beta-d-dioxolane nucleoside mit selektiver antihepatitis b-virus wirkung
MX9707453A (es) Derivados de quinazolina.
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
SE8801729D0 (sv) Purine derivatives for use in therapy
EP0620004A4 (en) MEDICAL COMPOSITION.
NL300041I2 (nl) Versterkingsmiddel voor het antineoplastisch effect en antineoplastisch middel.
DE69222698D1 (de) 4-desoxy-4-epipodophyllotoxinderivate oder deren pharmazeutisch akzeptierbaren salze
WO1990014831A3 (en) 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition
EP0412940A3 (en) Hydantoin or imidazolidinetrione derivatives for the prevention or treatment of renal failure
RU93049407A (ru) Производные бензимидазола и лекарственное средство с антагонистическим в отношении ангиотензина действием
IL97054A0 (en) Pharmaceutical compositions comprising buspirones for the treatment of sleep apneas
IL84096A0 (en) Therapeutic agent for the treatment of peptic ulcer disease comprising a purine derivative
ATE70977T1 (de) Medikamente fuer die behandlung von rheumatoider arthritis.
PT728002E (pt) Utilizacao de derivados de 2-amino purina para o tratamento e profilaxia da infeccao pelo virus de herpes 7 humano
KR900016130A (ko) 2-피리딜메틸티오 유도체 및 궤양 치료제
WO1990006116A3 (de) Mittel zur behandlung von chronisch entzündlichen darmerkrankungen
HK1012233A1 (en) Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections
ATE178800T1 (de) Pharmazeutische pentapeptid-zusammensetzung und ihre verwendung
IT1254361B (it) Formulazione farmaceutica per uso topico, indicata nel trattamento di infezioni virali della pelle e delle mucose.